starkly modern, brightly lit room filled with the gentle, hypnotic sound of running water. Pia felt a slight breeze against her as she advanced. She knew that was evidence of the room having positive pressure, meaning air came out of the room, not in. That was the opposite of the biosafety room, where the laminar flow was into the room.
Stepping beyond the door, Pia shaded her eyes against the sharp bluish light that came from banks of recessed fiber-optic fixtures. She assumed the light had something to do with sterility in the room. Stopping with the others, she took in the scene before her. They had entered a large space painted bright white. Pia was puzzled as to how this lab fit in with the rest of Rothman’s suite-it seemed larger than it feasibly could be. At the back of the room, a figure dressed in similar protective garb was hunched over a stainless-steel cart mounted on wheels, making some adjustments on a control panel. There were three rows of such carts and Pia counted thirty of them in all. Set atop each were clear rectangular Plexiglas aquarium-like containers of various sizes. Below were shelves holding various and sundry equipment. Each also had an attached pole supporting a control panel with an LED display. One of the carts was a few feet to Pia’s left and she moved over to take a closer look. Lesley and Will followed.
This was one of the organ-growing baths whose contained fluid was what Pia would be investigating for the month. She leaned over and peered into the container at a miniature translucent object suspended in the liquid by a kind of spiderweb that she was later to find out was made of the same material as real spiderwebs. As for the object itself, she could see it was connected by filament-thin lines to a central clamp where the lines were gathered. A thicker cable fed out of the bath and down into the body of the cart, where there was a boxy device with multiple readouts monitoring the conditions in the bath. An attached magnifying device on a movable arm was also connected to the cart. Pia maneuvered it into position so she could see the contained object better. Although it was not too much larger than a pine nut, its appearance was unmistakably that of a kidney, albeit a very tiny kidney. Most of the lines contained red fluid along one larger one that was clear. The red ones were presumably functioning as veins and arteries. The clear one was acting as the ureter to take away the urine the miniature organ was producing. To one side of the container was a jet, like one attached to a pool circulator, only in miniature. It was pulsating at a very rapid rate. Gentle eddies of liquid coursed around the container, causing the organ’s surface to pulsate slightly.
“We find that we must keep the fluid in the baths in constant motion despite the organs being perfused internally. But it has to be carefully modulated. Occasionally the rigid bath sets up a wash that can disturb the organ.” Yamamoto had stepped over to join the students. He noticed Pia straighten, looking down the length of the room.
“It’s quite something, isn’t it?” he said, speaking directly to her. “Of course, I see it every day, so I’ve come to take it all for granted.”
“How are the organs started?” Pia asked.
“They are started in tissue culture dishes designed to mimic the mouse uterine environment in terms of temperature and with pulsation waves close to the normal mouse heart rate of around five hundred and fifty beats a minute. As I said earlier, the whole process, first in the tissue culture dishes and then in these organ baths, is a ballet of gene expression with a careful adherence to sequence and timing. It starts with an aliquot of induced pluripotent stem cells held in close proximity by spiderweb-like restraints. Remember, to form a whole organ we have to involve all three germ layers: ectoderm, mesoderm, and endoderm. Once the organ has reached a size that can be manipulated, it is moved into these baths to develop to its full extent.”
“Are there other organs in here besides kidneys?” Will asked.
“Heavens yes,” Yamamoto said. “We’ve got all the usual transplantable organs such as livers, pancreases, lungs, and hearts so far. The kidney program is the most advanced, since it was kidneys we started with. To prove we are on track with what we have been doing, we have already transplanted some organs back into the individual mice from which the fibroblasts were taken with complete and utter success. And let me share another leap forward that we are in the process of making. We’ve found that carrying out organogenesis with multiple organs works even better than growing them singularly, meaning we have preparations in which the developing organs are helping each other, like the heart pumping the perfusing fluid and the kidneys removing waste.”
“Do you think sometime in the future you could essentially make a whole new organism?” Pia asked with astonishment and not a little dismay.
“At the rate we’re going, I see that as a definite possibility, although I can’t imagine what the rationale would be.”
Pia reflexively shuddered as she realized that Frankenstein, that nineteenth-century nightmare, could very well resurrect itself to haunt the twenty-first in a frighteningly more plausible fashion. If the Rothman-Yamamoto organogenesis worked well with kidneys, hearts, and pancreases, there was no reason it couldn’t work just as well with brains.
“Where are the human organs?” Pia asked.
Yamamoto took a few steps down the kidney line and pointed into a larger Plexiglas container. “This is human, as you might expect considering the size. It’s also one of the composite preparations with a human heart to do the kidney’s internal profusion.”
Pia stared into the bath, transfixed by what she was looking at. The kidney did look human, but the heart did not. She asked Yamamoto why.
“Good question. Since oxygenation of the perfusing fluid is being done by the oxygenator on the lower shelf, we did not need a four-chambered heart as two would do. So we altered the design of the heart.”
Once again Pia was amazed. “You have that much control of the organogenesis process to alter the overall three-dimensional architecture?”
“Absolutely. As I mentioned, once we made the original organogenesis breakthroughs, our progress has been truly phenomenal and isn’t slowing down.”
The figure Pia had seen earlier finished what he was doing, stood upright, and came toward the group. As he neared, and despite the surgical mask, Pia was further surprised. She could tell it was Rothman. Wearing some kind of goggles with thick, tinted lenses, he made for an eerie figure, like the prototypical mad scientist in his lair. Pia knew that what Dr. Yamamoto had said outside was true-this truly was groundbreaking work. In the stem cell race to move from the promising hypothetical to the clinical, Rothman and Yamamoto had advanced much further than any other team in the world.
Rothman moved the goggles to the top of his head as he came to a stop. He looked at Yamamoto. “Have they been given a short introduction?”
“Yes, Doctor.”
Rothman nodded. He knew he was going to have to show off his work to any number of interested biotech venture capitalists over the coming years, even though it wasn’t something he enjoyed or found easy. Yamamoto had helped him prepare a script that he’d practiced again and again with his wife. The students were to be a kind of dress rehearsal.
“Welcome to Columbia University Organogenesis Laboratory,” Rothman said. Yamamoto coughed gently into his hand. Rothman had trouble deviating even slightly from the prepared text.
“It is common knowledge that there are currently more than one hundred thousand people on waiting lists for organ transplants in this country, and these are people with end-stage disease. The list grows at a rate of about five hundred a month. Currently the same number of people, five hundred or so, die every month. On top of this grim statistic there are thousands upon thousands of additional patients who could benefit from an organ transplant even though they are not yet in a life-threatening situation. Obviously in the current environment the supply of viable organs from either a live donor or a recently deceased individual has not come close to keeping up with demand. Even for those patients lucky enough to receive an organ, the match is often far from optimal, meaning they are relegated to a life of immunosuppression with dire health consequences. What we are doing here, in a cost-conscious fashion, is to create organs which will simultaneously solve the supply problem and the immunological issue. This goal has not yet been reached, but we are making significant progress. At this stage we are looking for outside funding to ramp up production at multiple centers across the country.
“What you see in this row of baths are kidneys that have been created from stem cells derived from fibroblasts-connective tissue cells-of specific mice.” Yamamoto tried to interrupt to say that Rothman was covering material that had already been mentioned, but he couldn’t get Rothman’s attention. Rothman was on a roll. “I wear these magnifying lenses so I can work with the lines, but take my word for it, each organ is hooked up to a pump
